The oncology drug pipeline analysis market consists of various therapeutic drugs and molecules which are under clinical trial phases for effective treatment of different types of cancers. These drugs aim to improve survival rates, reduce side effects and provide better quality of life to cancer patients.
The global Oncology Drug Pipeline Analysis Market is estimated to be valued at US$ 188.20 Bn in 2023 and is expected to exhibit a CAGR of 13. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Cancer immunotherapy is one of the key trends contributing to the growth of the oncology drug pipeline analysis market. Immunotherapy helps boost patient's immune system to fight cancer cells more effectively. Various new immunotherapy treatments such as immune checkpoint inhibitors, T-cell therapies etc. are under pipeline which may help in long term remission for cancer patients. For example, new immunotherapy drugs under trial are showing promise for treatment of various cancers including lung cancer, bladder cancer and melanoma.
Segment Analysis
The oncology drug pipeline market can be segmented by cancer type into breast cancer, lung cancer, colorectal cancer, prostate cancer, blood cancer, and others. The breast cancer segment held the largest share of the market in 2022 owing to the increasing prevalence of breast cancer worldwide and growing R&D investment by key players to develop novel targeted therapies for breast cancer treatment.
Key Takeaways
The Global Oncology Drug Pipeline Market Demand is expected to witness high growth, exhibiting a CAGR of 13% over the forecast period, due to increasing research and development activities by pharmaceutical companies and growing prevalence of cancer cases globally.
Regional analysis
North America dominated the market in 2022 and is expected to remain dominant during the forecast period. This is attributed to increased healthcare spending, presence of major players, and availability of advanced healthcare facilities in the region. Asia Pacific is anticipated to exhibit the fastest growth owing to rising cancer incidence, growing healthcare expenditure, and increasing government focus on cancer treatment in emerging Asian countries.
Key players
Key players operating in the oncology drug pipeline market are F. HOFFMANN-LA ROCHE AG, PFIZER, INC., ASTELLAS PHARMA INC., NOVARTIS INTERNATIONAL AG, ASTRAZENECA PLC, BRISTOL-MYERS SQUIBB COMPANY, ABBVIE INC., AMGEN, INC., MERCK & CO., INC., JOHNSON & JOHNSON. These players are focusing on expanding their product portfolios through acquisitions and partnerships with local players to strengthen their market presence.
Explorer more information on this topic, Please visit -
